Novo Nordisk will continue offering its top-selling insulin brand, Mixtard, in vial form in India, despite phasing out Penfill cartridges. This decision follows concerns about the discontinuation ...

In a move which could shake up the diabetes market, Novo Nordisk is discontinuing the country’s largest selling insulin, Human Mixtard, among other older insulin brands in India. Human Mixtard ...

Small molecules with big potential The two drugs used in this study are already approved to treat rare cancers. Tazemetostat, known under the brand name Tazverik, was approved by the U.S. FDA in ...

Novo Nordisk’s insulin brand Mixtard will continue to be available in vials, the Danish healthcare company clarified, even as it phases out its penfill. The penfill is being phased out as part ...

A group of experts updated the FITTER insulin injection recommendations for the first time since 2016. The report includes new guidance on needle size and the angle at which injections should be ...

Semglee has been approved for over a year as a regular biosimilar to Lantus (insulin glargine), meaning that it could be used in place of Sanofi's drug, but only if specifically prescribed for a ...

The board voted to add their name to a lawsuit alleging that insulin is unfairly overpriced in the United States at their March 18 meeting. If successful, the suit could result in a payout of ...

A Sanofi subsidiary has claimed FDA approval for the first biosimilar of Novo Nordisk's Novolog, an older formulation of the Danish pharma's blockbuster insulin analogue product insulin aspart.

These medications were originally developed to manage type 2 diabetes, as they help stabilize glucose and boost insulin secretion. However, doctors noticed that patients on treatment reduced their ...

When a GLP-1 RA is prescribed along with insulin, it can increase the odds of hypoglycemia. Because GLP-1 RAs slow digestion, they may affect how some medications are absorbed. If you have ...

Data Sources: PubMed was searched (to December 5, 2011) using the terms exenatide, liraglutide, albiglutide, and lixisenatide. The search was limited to studies published in English and conducted ...

Thirty-seven-year-old Nupur Lalvani, who has been living with Type 1 diabetes since the age of eight, was dependent on insulin pens and had of late been a regular user of Novo Nordisk’s largest ...